參考文獻(xiàn)/References:
[1] 羅凱燕,喻姣花.骨科護(hù)理學(xué)[M].北京:中國協(xié)和醫(yī)科大學(xué)出版社,2005:413.
[2] 國家中醫(yī)藥管理局.中醫(yī)病證診斷療效標(biāo)準(zhǔn)[S].南京:南京大學(xué)出版社,1994:27.
[3] Anaforoglu I,Nar-Demirer A,Bascil-Tutuncu N,et al.Prevalence of osteoporosis and factors affecting bone mineral density among postmenopausal Turkish women with type 2 diabetes[J].J Diabetes Complications,2009,23(1):12-17.
[4] Tóth E,Csupor E,Mészáros S,et al.The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures-an open label study[J].Bone,2005,36(1):47-51.
[5] de Liefde Ⅱ,van der Klift M,de Laet CE,et al.Bone mineral density and fracture risk in type-2 diabetes mellitus:the Rotterdam study[J].Osteoporos Int,2005,16(12):1713-1720.
[6] 劉忠厚.骨質(zhì)疏松學(xué)[M].北京:科學(xué)出版社,1998:161-162.
[7] Takahashi S,Goldring S,Katz M,et al.Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation[J].J Clin Invest,1995,95(1):167-171.
[8] Wilson JD,Foser DW.Williams textbook of endocrinology[M].8th ed.Philadelphia: Lippincott-Raven Publisher,1992:1415-1423.
[9] Civitelli R,Connelli S,Zacchei F,et al.Bone turnover in postmenopausal osteoporosis.Effect of calcitonin treatment[J].J Clin Invest,1988,82(4):1268-1274.